Skip to content
PeptideAgent

Compounding pharmacies in Indiana

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Indiana Board of Pharmacy (Indiana Professional Licensing Agency) regulates compounding pharmacies in Indiana. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Indiana at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Indiana

No verified compounding pharmacies serving Indiana are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Indiana

The Indiana Board of Pharmacy, administered by the Professional Licensing Agency, regulates pharmacies under Indiana Code Title 25, Article 26 and Title 856 of the Indiana Administrative Code. Indiana follows the federal 503A framework for which substances may be compounded (approved drug component, USP or NF monograph, or FDA 503A bulks list), and Senate Enrolled Act 282 (2026) adds a state layer: bulk drug substances used for compounding must be manufactured by an FDA-registered establishment and be accompanied by a certificate of analysis, with most provisions effective July 1, 2026. The same act creates medical spa registration with the Medical Licensing Board of Indiana starting January 1, 2027, including a responsible practitioner and serious adverse event reporting, which reaches weight-loss and wellness clinics that administer compounded drugs. Pharmacies outside Indiana that ship prescription drugs to Indiana patients must hold an Indiana nonresident pharmacy license under Indiana Code 25-26-17. The enrolled act (Public Law 136, signed March 5, 2026) adds Indiana Code 16-42-22.5, effective July 1, 2026, which bars compounding unless the bulk drug substance is not research grade (outside an IRB-approved study) or veterinary grade, was made by an establishment registered with FDA as a human drug establishment, comes with a valid certificate of analysis stating its identity, content, and country of original manufacture, and has had quality control testing, and unless the compounding complies with the federal Food, Drug, and Cosmetic Act and applicable USP chapters. On Board request, a nonresident pharmacy shipping compounded drugs into Indiana must document compliance, and sellers must keep bulk substance records for two years after the last lot expires. Sterile preparation standards are in the Board's rules at 856 IAC 1, Rule 30 (sterile pharmaceuticals). [1] [3] [4] [5] [6] [7]

Compounded GLP-1 access in Indiana

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Indiana's 2026 law adds sourcing rules (FDA-registered bulk manufacturers with certificates of analysis) that exclude the unregistered active ingredient suppliers behind many cheap compounded GLP-1 products. Medical spas offering GLP-1 injections will need to register with the Medical Licensing Board from January 1, 2027. [5] [10]

Research use only sellers in Indiana

Only Indiana-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Indiana patients, and Senate Enrolled Act 282 (2026) requires compounders to source bulk substances from FDA-registered establishments. Indiana Code 16-42-22.5, added by that act, expressly bars compounding with a research grade bulk substance outside an IRB-approved study. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and do not meet Indiana's new sourcing standard. [3] [5] [6] [11]

Indiana notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth under Indiana Code 25-1-9.5. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and Indiana compounders must now use FDA-registered bulk sources with a certificate of analysis. [2] [5] [10]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. Even if it becomes eligible, Indiana's 2026 law requires the bulk substance to come from an FDA-registered establishment with a certificate of analysis. [5] [8] [9]

How to check a compounding pharmacy in Indiana

  1. Search the Indiana Board of Pharmacy (Indiana Professional Licensing Agency) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Indiana requires before it ships to you. [1] [3] [4] [5] [6] [7]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Indiana. [3] [5] [6] [11]

Common questions in Indiana

What did Indiana's 2026 compounding law change?

Senate Enrolled Act 282, signed March 5, 2026, requires bulk drug substances used in compounding to come from FDA-registered manufacturers with a certificate of analysis, mostly effective July 1, 2026, and requires medical spas to register with the Medical Licensing Board beginning January 1, 2027. [5]

What does an out-of-state pharmacy need to ship compounded peptides to Indiana?

An Indiana nonresident pharmacy license from the Indiana Board of Pharmacy under Indiana Code 25-26-17. Check the Professional Licensing Agency lookup before ordering. [1] [6]

All peptide legal questions for Indiana

Sources

  1. [1]Indiana Board of Pharmacy, Indiana Professional Licensing Agency
  2. [2]Indiana Code Title 25, Article 1, Chapter 9.5, Telehealth services and prescriptions
  3. [3]Senate Enrolled Act 282 (2026), enrolled text, Public Law 136, adding Indiana Code 16-42-22.5
  4. [4]856 Indiana Administrative Code Article 1, Pharmacies and Pharmacists (including Rule 30, sterile pharmaceuticals)
  5. [5]Indiana General Assembly, Senate Bill 282 (2026), Compounding drugs; registration of medical spas
  6. [6]Indiana Code Title 25, Article 26, Chapter 17, Nonresident pharmacies
  7. [7]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  9. [9]FDA: Pharmacy Compounding Advisory CommitteeFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts